Brokerage Call | CLSA keeps ‘underperform’ rating on Dr Reddy’s Laboratories, target price at Rs 1,120
#1 Earnings in-line with estimates
#2 Expects US base business to be flat or grow at single-digits YoY & steady growth in other markets
#3 gRevlimid sales expected to start tapering from Q3FY26
#4 Partly offset by launch of Semaglutide in markets like Canada & India
r Reddys Laboratories
At 12:56 hrs Dr Reddys Laboratories was quoting at Rs 1,282.00, up Rs 34.45, or 2.76 percent.
It has touched an intraday high of Rs 1,287.90 and an intraday low of Rs 1,255.05.
It was trading with volumes of 181,648 shares, compared to its five day average of 70,138 shares, an increase of 158.99 percent.
In the previous trading session, the share closed up 0.58 percent or Rs 7.15 at Rs 1,247.55.
The share touched a 52-week high of Rs 1,420.20 and a 52-week low of Rs 1,025.90 on 21 August, 2024 and 07 April, 2025, respectively.
Currently, the stock is trading 9.73 percent below its 52-week high and 24.96 percent above its 52-week low.
Market capitalisation stands at Rs 106,993.38 crore.
